Who is sponsoring NCT05156450?

NCT05156450 is sponsored by West China Hospital.

What condition does NCT05156450 study?

NCT05156450 studies Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination.

Is NCT05156450 still recruiting?

NCT05156450 is currently status unknown. Last updated 14 December 2021.

Last reviewed 2021-12-14 · How we verify

NCT05156450

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Status unknown Phase 2 Last updated 14 December 2021

What this trial tests

Phase 2 trial testing TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Prostatic Neoplasms, Castration-Resistant in 30 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
1 October 2023

1 January 2024

Quick facts

Lead sponsor	West China Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2022
Primary completion	1 October 2023
Estimated completion	1 January 2024
Sites	1 location across China

Drugs / interventions tested

TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone — full drug profile →

Conditions studied

Prostatic Neoplasms, Castration-Resistant — all drugs for Prostatic Neoplasms, Castration-Resistant →
Drug Therapy, Combination — all drugs for Drug Therapy, Combination →

Sponsor

West China Hospital

Who can join

Adults 18 to 80, male only, with Prostatic Neoplasms, Castration-Resistant or Drug Therapy, Combination. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase Ib/II clinical study of TQB3616 capsules in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer, to determine the dose for further clinical studies and to evaluate the safety and efficacy of this combined therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and Future.
Siskin M, Economides MP, Wise DR. · · 2025 · cited 7× · PMID 40075623 · DOI 10.3390/cancers17050774
The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages.
Pedrani M, Barizzi J, Salfi G, Nepote A, et al · · 2025 · cited 5× · PMID 39796175 · DOI 10.3390/ijms26010318
Interactions between key genes and pathways in prostate cancer progression and therapy resistance.
Wu F, Zhang H, Hao M. · · 2025 · cited 4× · PMID 39917165 · DOI 10.3389/fonc.2025.1467540
Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.
Safaroghli-Azar A, Mekonnen LB, Lenjisa J, Milne R, et al · · 2026 · PMID 41943159 · DOI 10.1186/s13045-026-01794-7

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasms, Castration-Resistant

Currently open trials in the same condition.

NCT07225946 — A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Canc · Phase 3 · recruiting
NCT06706921 — 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer · Phase 4 · recruiting
NCT06353386 — Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Particip · Phase 1, PHASE2 · recruiting
NCT05743621 — Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · recruiting
NCT05393791 — Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC · Phase 2 · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05156450 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 14 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing